BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12628841)

  • 1. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.
    Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
    Eur J Cancer; 2003 Mar; 39(5):622-30. PubMed ID: 12628841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
    Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
    Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
    Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
    Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
    Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target.
    Hagerling C; Owyong M; Sitarama V; Wang CY; Lin C; van den Bijgaart RJE; Koopman CD; Brenot A; Nanjaraj A; Wärnberg F; Jirström K; Klein OD; Werb Z; Plaks V
    BMC Cancer; 2020 Jun; 20(1):542. PubMed ID: 32522170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
    Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
    Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
    Allred DC
    J Natl Cancer Inst; 2010 May; 102(9):585-7. PubMed ID: 20427432
    [No Abstract]   [Full Text] [Related]  

  • 16. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relationships between HER2 Overexpression and DCIS Characteristics.
    Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
    Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.